Pre- and Post-partum Levels of Serum Visfatin in Pregnant Women with Gestational Diabetes Mellitus: A Correlation
Keywords:
Visfatin, Gestational Diabetes Mellitus, InsulinAbstract
Introduction: Gestational diabetes mellitus is glucose intolerance diagnosed or detected for the first-time during pregnancy and has serious implications for fetal and maternal health if left untreated. Hyperglycemia during pregnancy is caused by the progressive increase in insulin resistance from mid to third trimester. Increased insulin resistance is a consequence of an increase in adipose tissue in mother and desensitizing effect to insulin by placental factors. Adipokine, visfatin, is multifunctional protein. Its levels are much higher in pregnant women.
Aims and Objectives: To determine and compare levels of serum visfatin and insulin resistance before and after delivery in gestational diabetics.
Place and Duration of Study: Lahore General Hospital Lahore/ PGMI, Lahore, during 2024.
Materials and Methods: It was a Case control study. 21 Pregnant females at gestational age of 32-36 weeks were selected using non-probability purposive sampling as diagnosed cases of GDM (OGTT) matched with 21 control without GDM. Serum levels of Visfatin, Insulin, fasting blood Glucose and HOMA IR were determined. Data was analyzed by using SPSS version 20. Results were checked for normality. Paired t test was used to compare normally distributed data before and after delivery in the both groups. The Wilcoxon sign rank test was used to compare non normally distributed data before and after delivery. Spearman’s and Pearson correlation was used to correlate data. A p-value of <0.05 was considered significant.
Results: A statistically significant difference (p-value=0.000) was determined between Serum visfatin and fasting insulin levels. A Statistically significant correlation (p-value=0.000) was found between Serum visfatin, insulin, FBG and HOMAIR before and after delivery.
Conclusion: In GDM women comparison of visfatin before and after delivery showed a significant difference indicating that source of visfatin is likely the placenta, which due to prolonged hyperglycemia causes the release of visfatin. A significant correlation supporting the belief that enhanced insulin resistance during pregnancy leads to hyperglycemia causing an increased level of visfatin.
References
Sokup, A., Ruszkowska-Ciastek, B., Góralczyk, K., Walentowicz, M., Szyma?ski, M. and Ro??, D., 2013. Insulin resistance as estimated by the homeostatic method at diagnosis of gestational diabetes: estimation of disease severity and therapeutic needs in a population-based study. BMC Endocr. Disord., 13(1): 21.
Iqbal, R., Rafique, G., Badruddin, S., Qureshi, R., Cue, R. and Gray-Donald, K., 2007. Increased body fat percentage and physical inactivity are independent predictors of gestational diabetes mellitus in South Asian women. Eur. J. Clin. Nutr., 61(6): 736- 742.
Leng, J., Shao, P., Zhang, C., Tian, H., Zhang, F., Zhang, S., Dong, L., Li, L., Yu, Z., Chan, J.C. and Hu, G., 2015. Prevalence of gestational diabetes mellitus and its risk factors in Chinese pregnant women: a prospective population-based study in Tianjin, China. PLoS One, 10(3): 012-029.
Kaaja, R. and Rönnemaa, T., 2008. Gestational diabetes: pathogenesis and consequences to mother and offspring. Rev. Diabet. Stud., 5(4): 194-202
Buchanan, T.A. and Xiang, A.H., 2005. Gestational diabetes mellitus, Eur. J. Clin. Invest., 115(3):485- 491.
Sonagra, A.D., Biradar, S.M., Dattatreya, K. and DS, J.M., 2014. Normal Pregnancy-A State of Insulin Resistance. JCDR., 8(11): 1-3.
Ruan, H., Zarnowski, M.J., Cushman, S.W. and Lodish, H.F., 2003. Standard isolation of primary adipose cells from mouse epididymal fat pads induces inflammatory mediators and down- regulates adipocyte genes. J. Biol. Chem., 278(48):.47585-47593.
Rezvan, N., Hosseinzadeh-Attar, M.J., Masoudkabir, F., Moini, A., Janani, L. and Mazaherioun, M., 2012. Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy. Arch. Gynecol. Obstet., 285(5): 1257-1262.
Kim, M.K.., Lee, J..H., Kim, H., Park, S..J., Kim, S..H., Kang, G.B., Lee, Y.S., Kim, J.B., Kim, K.K.., Suh, S.W. and Eom, S.H., 2006. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK- 866. J. Mol. Biol., 362(1): 66-77.
Morgan, S.A., Bringolf, J.B. and Seidel, E.R., 2008. Visfatin expression is elevated in normal human pregnancy. Peptides, 29(8): 1382-1389.
Garten, A., Petzold, S., Körner, A., Imai, S.I. and Kiess, W., 2009. Nampt: linking NAD biology, metabolism and cancer. TEM., 20(3): 130-138.
Masood, S.H., Memon, A.S. and Abbas, T.,2012. Study to Compare Serum Visfatin Concentration in Different Trimesters of Pregnancy. JPMC., 6(4): 907-911.
Zhou, J. and Seidel, E.R., 2010. Estrogens induce visfatin expression in 3T3-L1 cells. Peptides, 31(2): 271-274.
Krzyzanowska, K., Krugluger, W., Mittermayer, F., Rahman, R., Haider, D., Shnawa, N. and Schernthaner, G., 2006. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin. Sci., 110(5): 605-609.
Lewandowski, K.C., Stojanovic, N., Press, M., Tuck, S.M., Szosland, K., Bienkiewicz, M., Vatish, M., Lewinski, A., Prelevic, G.M. and Randeva, H.S., 2007. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia, 50(5): 1033-1037.
Ma, Y., Cheng, Y., Wang, J., Cheng, H., Zhou, S. and Li, X., 2010. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. Diabetes Res.Clin.Pract., 90(1): 60-65.
Gok, D.E., Yazici, M., Uckaya, G., Bolu, S.E., Basaran, Y., Ozgurtas, T., Kilic, S. and Kutlu, M., 2011. The role of visfatin in the pathogenesis of gestational diabetes mellitus. J. Endocrinol. Invest., 34(1): 3-7.
Chan, T.F., Chen, Y.L., Lee, C.H., Chou, F.H., Wu, L.C., Jong, S.B. and Tsai, E.M., 2006. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J. Soc. Gynecol. Investig., 13(5): 364-367.
Telejkoa, B., Kuzmickib, M., Zozenberga, A., Szamatowicza, J., Wawrusiewicz-Kuryloneka, N., Nikolajuka, A., Kretowskia, A., Gorkaa, M., 2009. Visfatin in gestational diabetes: serum level and mRNAexpression in fat and placental tissue. Diabetes Res. Clin. pract., 84(1): 68-75.
Akturk, M., Altinova, A.E., Mert, I., Buyukkagnici, U., Sargin, A., Arslan, M. and Danisman, N., 2008. Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester.
J. Endocrinol. Invest., 31(7): 610-613.
Arumugam, R., Horowitz, E., Lu, D., Collier, J.J., Ronnebaum, S., Fleenor, D. and Freemark, M., 2008. The Interplay of Prolactin and the Glucocorticoids in the Regulation of ?-Cell Gene Expression, Fatty Acid Oxidation and Glucose– Stimulated Insulin Secretion: Implications for Carbohydrates Metabolism in Pregnancy. Endocrinology, 149(11): 5401- 5414.
Haider, D.G., Schaller, G., Kapiotis, S., Maier, C., Luger, A. and Wolzt, M., 2006. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia, 49(8): 1909-1914.
Hebisch, G., Neumaier-Wagner, P.M., Huch, R. and von Mandach, U., 2004. Maternal serum interleukin-1?,-6 and-8 levels and potential determinants in pregnancy and peripartum. J. Perinat. Med., 32(6): 475-480.
Kalra, P. and Anakal, M., 2013. Peripartum management of diabetes. Indian J. Endocr. Metab., 17(7): 72.
Liang, Z., Wu, Y., Xu, J., Fang, Q. and Chen, D., 2016. Correlations of serum visfatin and metabolisms of glucose and lipid in women with gestational diabetes mellitus. J. Diabetes Investig., 7(2): 247-252.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Proceedings
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a 